Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.
(33/58)
(+info)
Functional virus-based polymer-protein nanoparticles by atom transfer radical polymerization.
(34/58)
(+info)
Identification of mutations conferring 5-azacytidine resistance in bacteriophage Qbeta.
(35/58)
(+info)
Crystal structure of the read-through domain from bacteriophage Qbeta A1 protein.
(36/58)
(+info)
Evolution and protein packaging of small-molecule RNA aptamers.
(37/58)
(+info)
Cell targeting with hybrid Qbeta virus-like particles displaying epidermal growth factor.
(38/58)
(+info)
Colorful virus-like particles: fluorescent protein packaging by the Qbeta capsid.
(39/58)
(+info)
Glycan-targeted virus-like nanoparticles for photodynamic therapy.
(40/58)
(+info)